Document is current
Any future updates will be listed below
-
Authors
Tavira, Adriana
Basurco, Leyre
Abellanas, Miguel Angel
Ayerra, Leyre
Vidaurre, Clara
Luquin, Esther
Vales, Africa
Gonzalez-Aseguinolaza, Gloria
Marrodan, Lucia
Alonso, Marta M.
Mengual, Elisa
Tansey, Malú Gámez
Hervás-Stubbs, Sandra
Aymerich, Maria S.
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia, Innovación y Universidades (PID2023-151392OB-I00, PID2023-151392OB-I00, PID2023-151392OB-I00, PID2023-151392OB-I00, PID2023-151392OB-I00, PID2023-151392OB-I00)
Fundación Gangoiti
Ministerio de Universidades (FPU21/01545, FPU018/02244, FPU19/03255)
Instituto de Salud Carlos III (PI20/01063, PI20/01063, PI20/01063, PI20/01063)
Gobierno de Navarra (PC 192-193, PC 192-193, PC 192-193, PC 192-193)
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 16 September 2025
First Online: 11 November 2025
Competing interests
: M.G.T. has patent #US 11,365,229 B2 “Methods of treating neurological diseases,” issued to XENCOR, INC, Monrovia, CA (US). M.G.T. has patent #US7,144,987 B1 issued to Xencor, Inc., Monrovia, CA. M.G.T. has patent #US7,244,823 B2 issued to Xencor, Inc., Monrovia, CA. M.G.T. is an ex-employee of Xencor Inc., where she co-invented the DN-TNFs. She is a consultant to INmune Bio, which licensed XPro1595 for neurological indications and holds stock in the company. M.G.T. is Editor-in-Chief of npj Parkinson’s disease . The other authors declare no competing interests.
